CCO Oncology Podcast

Expert Answers to Questions on Contemporary Management of Hemophilia A

Episode Summary

In this podcast episode, listen to Michael Callaghan, MD; Miguel A. Escobar, MD; and Rebecca Kruse-Jarres, MD, MPH, as they answer questions from a clinician audience on new and established approaches for managing hemophilia A in pediatric and adult patients.

Episode Notes

In this episode, Michael Callaghan, MD; Miguel A. Escobar, MD; and Rebecca Kruse-Jarres, MD, MPH, answer questions from a clinician audience on topics related to hemophilia management including:

• Maintaining long-term musculoskeletal health
• Identifying patients most likely to benefit from pharmacokinetics-guided prophylaxis
• Managing combination therapies in older patients with comorbidities
• Youngest age at which patients can be considered for emicizumab
• Development of resistance to emicizumab
• Switching recombinant factor therapies
• Using bypassing agents with emicizumab for breakthrough bleeds in patients with inhibitors
• Potential clinical role of extending FVIII half-life with BIVV001
• Considerations when dosing emicizumab monthly

Presenters:

Michael Callaghan, MD
Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Children’s Hospital of Michigan
Detroit, Michigan

Miguel A. Escobar, MD
Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Rebecca Kruse-Jarres, MD, MPH
Professor
Department of Medicine
University of Washington
Executive/Medical Director
Washington Institute for Coagulation
Seattle, Washington

Content supported by educational grants from Genentech, a member of the Roche Group; Sanofi Genzyme Corporation; and Takeda Pharmaceutical Company Ltd.

Link to full program, including downloadable slidesets, expert commentaries, and on-demand Webcast: http://bit.ly/2MW5uhi